Iovance Biotherapeutics (IOVA) Current Assets (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Current Assets of $466.5 million for Q1 2026, down 9.0% year-over-year from $512.6 million in Q1 2025, and up 5.38% quarter-over-quarter from $442.7 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Current Assets (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Current Assets for 17 consecutive years, with $466.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 9.0% year-over-year to $466.5 million; the TTM figure through Mar 2026 stood at $466.5 million (down 9.0% YoY), while the FY2025 annual figure was $442.7 million, down 3.14% from the prior year.
- Current Assets climbed to $466.5 million in Q1 2026 per IOVA's latest filing, from $442.7 million in the prior quarter.
- Across five years, Current Assets topped out at $637.8 million in Q1 2023 and bottomed at $274.9 million in Q2 2023.
- Historically, Current Assets has averaged $432.6 million across 5 years, with a median of $431.6 million in 2022.
- On a YoY basis, Current Assets climbed as much as 48.46% in 2024 and fell as far as 39.55% in 2024.
- Iovance Biotherapeutics' Current Assets stood at $479.1 million in 2022, then sank by 35.75% to $307.8 million in 2023, then surged by 48.46% to $457.0 million in 2024, then slipped by 3.14% to $442.7 million in 2025, then advanced by 5.38% to $466.5 million in 2026.
- Business Quant data shows IOVA's Current Assets at $466.5 million in Q1 2026, $442.7 million in Q4 2025, and $429.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 464.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 464.26 Mn |
| Mar 31, 2026 | 466.50 Mn |
| Dec 31, 2025 | 442.69 Mn |
| Sep 30, 2025 | 429.09 Mn |
| Jun 30, 2025 | 422.50 Mn |
| Mar 31, 2025 | 512.65 Mn |
| Dec 31, 2024 | 457.02 Mn |
| Mar 31, 2024 | 385.53 Mn |
| Dec 31, 2023 | 307.85 Mn |
| Sep 30, 2023 | 382.59 Mn |
| Jun 30, 2023 | 274.88 Mn |
| Mar 31, 2023 | 637.78 Mn |
| Dec 31, 2022 | 479.12 Mn |
| Sep 30, 2022 | 369.88 Mn |
| Jun 30, 2022 | 431.59 Mn |
| Mar 31, 2022 | 489.97 Mn |
| Dec 31, 2021 | 507.96 Mn |
| Sep 30, 2021 | 583.03 Mn |
| Jun 30, 2021 | 666.64 Mn |
| Mar 31, 2021 | 605.22 Mn |